McDermott Will & Emery advised Corteria Pharmaceuticals on the deal. Corteria Pharmaceuticals, a French biotechnology company specializing in the development of interceptive therapies for heart failure...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here